Your browser doesn't support javascript.
loading
Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient
Jonathan Klein; Anderson F. Brito; Paul Trubin; Peiwen Lu; Patrick Wong; Tara Alpert; Mario A. Pena-Hernandez; Winston Haynes; Kathy Kamath; Feimei Liu; Chantal B.F. Vogels; Joseph R. Fauver; Carolina Lucas; Jieun Oh; Tianyang Mao; Julio Silva; Anne L. Wyllie; Catherine Muenker; Arnau Casanovas-Massana; Adam J. Moore; Mary E. Petrone; Chaney C. Kalinich; - IMPACT Research Team; Charles Dela Cruz; Shelli Farhadian; Aaron Ring; John Shon; Albert I. Ko; Nathan D. Grubaugh; Benjamin Israelow; Akiko Iwasaki; Marwan M. Azar.
Affiliation
  • Jonathan Klein; Yale School of Medicine
  • Anderson F. Brito; Yale School of Medicine
  • Paul Trubin; Yale School of Medicine
  • Peiwen Lu; Yale School of Medicine
  • Patrick Wong; Yale School of Medicine
  • Tara Alpert; Yale School of Medicine
  • Mario A. Pena-Hernandez; Yale School of Medicine
  • Winston Haynes; SerImmune Inc.
  • Kathy Kamath; SerImmune Inc.
  • Feimei Liu; Yale School of Medicine
  • Chantal B.F. Vogels; Yale School of Medicine
  • Joseph R. Fauver; Yale School of Medicine
  • Carolina Lucas; Yale School of Medicine
  • Jieun Oh; Yale School of Medicine
  • Tianyang Mao; Yale School of Medicine
  • Julio Silva; Yale School of Medicine
  • Anne L. Wyllie; Yale School of Medicine
  • Catherine Muenker; Yale School of Medicine
  • Arnau Casanovas-Massana; Yale School of Medicine
  • Adam J. Moore; Yale School of Medicine
  • Mary E. Petrone; Yale School of Medicine
  • Chaney C. Kalinich; Yale School of Medicine
  • - IMPACT Research Team; Yale School of Medicine
  • Charles Dela Cruz; Yale School of Medicine
  • Shelli Farhadian; Yale School of Medicine
  • Aaron Ring; Yale School of Medicine
  • John Shon; SerImmune Inc.
  • Albert I. Ko; Yale School of Medicine
  • Nathan D. Grubaugh; Yale School of Medicine
  • Benjamin Israelow; Yale School of Medicine
  • Akiko Iwasaki; Yale School of Medicine
  • Marwan M. Azar; Yale School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-21253992
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
Prior to the emergence of antigenically distinct SARS-CoV-2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses. However, case reports also suggested that rare, repeated infections may occur as soon as 48 days following initial disease onset. The underlying immunologic deficiencies enabling SARS-CoV-2 reinfections are currently unknown. Here we describe a renal transplant recipient who developed recurrent, symptomatic SARS-CoV-2 infection - confirmed by whole virus genome sequencing - 7 months after primary infection. To elucidate the immunological mechanisms responsible for SARS-CoV-2 reinfection, we performed longitudinal profiling of cellular and humoral responses during both primary and recurrent SARS-CoV-2 infection. We found that the patient responded to the primary infection with transient, poor-quality adaptive immune responses. The patients immune system was further compromised by intervening treatment for acute rejection of the renal allograft prior to reinfection. Importantly, we also identified the development of neutralizing antibodies and the formation of humoral memory responses prior to SARS-CoV-2 reinfection. However, these neutralizing antibodies failed to confer protection against reinfection, suggesting that additional factors are required for efficient prevention of SARS-CoV-2 reinfection. Further, we found no evidence supporting viral evasion of primary adaptive immune responses, suggesting that susceptibility to reinfection may be determined by host factors rather than pathogen adaptation in this patient. In summary, our study suggests that a low neutralizing antibody presence alone is not sufficient to confer resistance against reinfection. Thus, patients with solid organ transplantation, or patients who are otherwise immunosuppressed, who recover from infection with SARS-CoV-2 may not develop sufficient protective immunity and are at risk of reinfection.
License
cc_no
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2021 Document type: Preprint
...